Ten-minute Introduction from our discussion group leaders:

• Where we have come from—Old-fashioned ways of treating autoimmune disease
• Where we are now—The prevalence of inhibiting the immune system, challenges, and weaknesses
• What’s next? The ‘Brave New World’ of immunology—Re-education of the immune system, benefits, and challenges

Discussion Topics:

• Inhibition vs re-education of the immune system
• What novel technologies in the field are emerging?
• What challenges are scientists facing?

Discussion Leader:

• Paul Eggleton, Senior Director of Immunology at RevoloBio
• Roly Foulkes, Chief Scientific Officer at RevoloBio

April 2022

• Presentation: ‘The Value of In Vivo Imaging in the Clinical Development of IO Drugs,’ by Ian Wilson, Chief Executive Officer at ImaginAb
• Discovering and validating relevant biomarkers to facilitate rapid novel immunotherapy development 
• Utility of biomarkers in preclinical and clinical drug development 
• Unmet market needs: improving clinical translation and pharmacodynamic response 

Discussion Leaders:

• Ian Wilson, Chief Executive Officer at ImaginAb
  
• John Rossi, Head of Translational Medicine, SVP Research at Cero Therapeutics 

March 2022

• Presentation: “What are the regulatory changes going to be in Europe and the UK”?, by Patrick Fivey, Director, Precision Medicine Policy, AstraZeneca
• Overcoming regulatory hurdles in IO 
• Assessing the type of cancer to which immunotherapy will be most beneficial and implementing it in a personalised approach 
• Exploring the evolution of effective precision immunotherapies 
• Optimising response and minimising resistance 
  
  

Discussion Leaders:

• Patrick Fivey, Director, Precision Medicine Policy, AstraZeneca 
• Roy Milner, Associate Regulatory Affairs Director, AstraZeneca  
  
  

February 2022

Discussion Topics:

• Presentation: The Opportunities and Challenges of Preclinical Modelling, by Bonnie Hammer, Senior Vice President, R&D at Inverna   
• Aligning goals with technologies in preclinical oncology studies 
• Integrative tumour modelling approaches 
• Decreasing rate of translational & clinical failures through advanced models

   

Discussion Group Leaders:

• Bonnie Hammer, Senior Vice President, R&D at Inverna 
• Pellin Candarlioglu, Cell Biologist/ Bioengineer, Complex In Vitro Models, GSK

October 2021

Join us for a one hour discussion on understanding the tumour microenvironment with advanced technologies. Our live event aims to bring together key opinion leaders discussing cutting-edge research into the area: from markers through to state of the art technologies to understanding immune response through to cell types of interests in tumour indications, do not miss out on attending the session to stay at the forefront of research.

Panel Discussion: Peripheral Markers To Help Understand The Tumour Microenvironment

• What are the markers for the tumour microenvironment? 
• Technologies for understanding immune response 
  – Multiplex technologies 
  – Multi-omics technologies 
• Cell types of interests in tumour indications

Moderator: Paul Jones, Biomarkers Lead, UCB

Panellists:

John Rossi, Senior Vice President and Head of Translational Medicine, Cero Therapeutics 

Siddha Kasar, Clinical Translational Lead of Cell Therapies, Takeda